These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 37586058)

  • 1. Combined Antibodies Evusheld against the SARS-CoV-2 Omicron Variants BA.1.1 and BA.5: Immune Escape Mechanism from Molecular Simulation.
    Zhang J; Cong Y; Duan L; Zhang JZH
    J Chem Inf Model; 2023 Aug; 63(16):5297-5308. PubMed ID: 37586058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
    Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
    Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5.
    Touret F; Baronti C; Pastorino B; Villarroel PMS; Ninove L; Nougairède A; de Lamballerie X
    Sci Rep; 2022 Jul; 12(1):12609. PubMed ID: 35871089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
    Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
    Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
    J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
    Shah M; Woo HG
    Front Immunol; 2021; 12():830527. PubMed ID: 35140714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment.
    Focosi D; Casadevall A
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.
    Dong J; Zost SJ; Greaney AJ; Starr TN; Dingens AS; Chen EC; Chen RE; Case JB; Sutton RE; Gilchuk P; Rodriguez J; Armstrong E; Gainza C; Nargi RS; Binshtein E; Xie X; Zhang X; Shi PY; Logue J; Weston S; McGrath ME; Frieman MB; Brady T; Tuffy KM; Bright H; Loo YM; McTamney PM; Esser MT; Carnahan RH; Diamond MS; Bloom JD; Crowe JE
    Nat Microbiol; 2021 Oct; 6(10):1233-1244. PubMed ID: 34548634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.
    Huang M; Wu L; Zheng A; Xie Y; He Q; Rong X; Han P; Du P; Han P; Zhang Z; Zhao R; Jia Y; Li L; Bai B; Hu Z; Hu S; Niu S; Hu Y; Liu H; Liu B; Cui K; Li W; Zhao X; Liu K; Qi J; Wang Q; Gao GF
    Immunity; 2022 Aug; 55(8):1501-1514.e3. PubMed ID: 35777362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
    Bruel T; Stéfic K; Nguyen Y; Toniutti D; Staropoli I; Porrot F; Guivel-Benhassine F; Bolland WH; Planas D; Hadjadj J; Handala L; Planchais C; Prot M; Simon-Lorière E; André E; Baele G; Cuypers L; Mouthon L; Mouquet H; Buchrieser J; Sève A; Prazuck T; Maes P; Terrier B; Hocqueloux L; Schwartz O
    Cell Rep Med; 2022 Dec; 3(12):100850. PubMed ID: 36450283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring.
    Brady T; Zhang T; Tuffy KM; Haskins N; Du Q; Lin J; Kaplan G; Novick S; Roe TL; Ren K; Rosenthal K; McTamney PM; Abram ME; Streicher K; Kelly EJ
    Microbiol Spectr; 2022 Oct; 10(5):e0103422. PubMed ID: 35993765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
    He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
    Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages.
    Driouich JS; Cochin M; Lingas G; Luciani L; Baronti C; Bernadin O; Gilles M; Villarroel PMS; Moureau G; Petit PR; Dupont A; Izopet J; Kamar N; Autran B; Paintaud G; Caillard S; le Bourgeois A; Richez C; Couzi L; Xhaard A; Marjanovic Z; Avouac J; Jacquet C; Anglicheau D; Cheminant M; Nguyen S; Terrier B; Gottenberg JE; Besson C; Letrou S; Tine J; Basilua JM; Angoulvant D; Tardivon C; Blancho G; Martin-Blondel G; Yazdanpanah Y; Mentré F; Lévy V; Touret F; Guedj J; de Lamballerie X; Nougairède A
    Biomed Pharmacother; 2024 Aug; 177():116988. PubMed ID: 38897157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages.
    Touret F; Giraud E; Bourret J; Donati F; Tran-Rajau J; Chiaravalli J; Lemoine F; Agou F; Simon-Lorière E; van der Werf S; de Lamballerie X
    iScience; 2023 Apr; 26(4):106413. PubMed ID: 36968074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
    Zhou H; Dcosta BM; Landau NR; Tada T
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization.
    Xiong D; Zhao X; Luo S; Cong Y; Zhang JZH; Duan L
    J Phys Chem Lett; 2022 Jul; 13(26):6064-6073. PubMed ID: 35758899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
    Bruel T; Hadjadj J; Maes P; Planas D; Seve A; Staropoli I; Guivel-Benhassine F; Porrot F; Bolland WH; Nguyen Y; Casadevall M; Charre C; Péré H; Veyer D; Prot M; Baidaliuk A; Cuypers L; Planchais C; Mouquet H; Baele G; Mouthon L; Hocqueloux L; Simon-Loriere E; André E; Terrier B; Prazuck T; Schwartz O
    Nat Med; 2022 Jun; 28(6):1297-1302. PubMed ID: 35322239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
    Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
    Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies.
    Zhou H; Tada T; Dcosta BM; Landau NR
    bioRxiv; 2022 Feb; ():. PubMed ID: 35194604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.